Portola Pharmaceuticals’ promising antidote for blood thinners has attracted a who’s-who of Big Pharma partners, and now the biotech is advancing its reverser of Factor Xa inhibitors to Phase III with the help of Bayer and Johnson & Johnson.

…read more

Source: Portola takes its ‘breakthrough’ bleeding drug to PhIII with Bayer, J&J in tow


0 No comments